Diabetes and mucormycosis: A complex interplay

Diabetes and Metabolism

Volumn 38, Issue 3, 2012, Pages 193-204

  Rammaert, B ^a   Lanternier, F ^a,b   Poiree S ^c   Kania, R ^d   Lortholary, O ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Amphotericin B lipid derivatives; Diabetes; Mucormycosis (zygomycosis); Review; Sinusitis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; IRON; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIMICROBIAL THERAPY; CAUSE OF DEATH; CHEMOTAXIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUNNINGHAMELLA BERTHOLLETIAE; CYTOKINE PRODUCTION; DEBRIDEMENT; DEVELOPED COUNTRY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG PENETRATION; FIBEROPTIC BRONCHOSCOPY; FRANCE; FUNGAL SPORE GERMINATION; FUNGUS GROWTH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INDIA; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; MORTALITY; MUCORMYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PH; PHAGOCYTE; POLYMORPHONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREVALENCE; REVIEW; RHIZOMUCOR; RHIZOMUCOR PUSILLUS; SEDENTARY LIFESTYLE; SKIN BIOPSY; THROMBOCYTE FUNCTION;

ANIMALS; ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; MUCORMYCOSIS; OPPORTUNISTIC INFECTIONS; PHAGOCYTES; RISK FACTORS; SINUSITIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863460568     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.01.002     Document Type: Review

References (119)

1. WHO. Diabetes [Internet]; available from: [cited 2011 Mar 14]. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
2. Diamond J. Medicine: diabetes in India. Nature 2011, 469:478-479.
3. Bruno G., Landi A. Epidemiology and costs of diabetes. Transplant Proc 2011, 43:327-329.
4. Sun H.-Y., Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 2009, 48:745-755.
5. Chamilos G., Lewis R.E., Kontoyiannis D.P. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006, 50:96-103.
6. Lukács G., Papp T., Nyilasi I., Nagy E., Vágvölgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004, 42:5400-5402.
7. Galgóczy L., Papp T., Lukács G., Leiter E., Pócsi I., Vágvölgyi C. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive zygomycetes. FEMS Microbiol Lett 2007, 270:109-115.
8. Galgóczy L., Nyilasi I., Papp T., Vágvölgyi C. Are statins applicable for the prevention and treatment of zygomycosis?. Clin Infect Dis 2009, 49:483. [author reply 484-5].
9. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
10. Rüping M.J.G.T., Heinz W.J., Kindo A.J., Rickerts V., Lass-Flörl C., Beisel C., et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010, 65:296-302.
11. Skiada A., Pagano L., Groll A., Zimmerli S., Dupont B., Lagrou K., et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011, 17:1859-1867.
12. Lanternier F., Dannaoui E., Morizot G., Elie C., Garcia-Hermoso D., Bitar D., et al. A global analysis of mucormycosis in France: the "RetroZygo study" (2005-2007). Clin infect dis 2012, 54:S35-S43.
13. Chakrabarti A., Das A., Mandal J., Shivaprakash M.R., George V.K., Tarai B., et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006, 44:335-342.
14. Bitar D., Van Cauteren D., Lanternier F., Dannaoui E., Che D., Dromer F., et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009, 15:1395-1401.
15. Zaoutis T.E., Roilides E., Chiou C.C., Buchanan W.L., Knudsen T.A., Sarkisova T.A., et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis. J 2007, 26:723-727.
16. Rammaert B., Lanternier F., Zahar J., Dannaoui E., Bougnoux M.-E., Lecuit M., et al. Healthcare-associated mucormycosis. Clin Infect Dis 2012, 54:S44-S54.
17. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
18. Singh N., Aguado J.M., Bonatti H., Forrest G., Gupta K.L., Safdar N., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009, 200:1002-1011.
19. Pagano L., Offidani M., Fianchi L., Nosari A., Candoni A., Piccardi M., et al. Mucormycosis in hematologic patients. Haematologica 2004, 89:207-214.
20. Almyroudis N.G., Sutton D.A., Linden P., Rinaldi M.G., Fung J., Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006, 6:2365-2374.
21. Wickline C.L., Cornitius T.G., Butler T. Cellulitis caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin infusion pump therapy. South Med J 1989, 82:1432-1434.
22. Quinio D., Karam A., Leroy J.P., Moal M.C., Bourbigot B., Masure O., et al. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 2004, 42:177-180.
23. Hampson F.G., Ridgway E.J., Feeley K., Reilly J.T. A fatal case of disseminated zygomycosis associated with the use of blood glucose self-monitoring equipment. J Infect 2005, 51:e269-e272.
24. Szalai G., Fellegi V., Szabó Z., Vitéz L.C. Mucormycosis mimicks sinusitis in a diabetic adult. Ann N Y Acad Sci 2006, 1084:520-530.
25. Kim J., Fortson J.K., Cook H.E. A fatal outcome from rhinocerebral mucormycosis after dental extractions: a case report. J Oral Maxillofac Surg 2001, 59:693-697.
26. Boyce J.M., Lawson L.A., Lockwood W.R., Hughes J.L. Cunninghamella bertholletiae wound infection of probable nosocomial origin. South Med J 1981, 74:1132-1135.
27. Eschard J.P., Poynard J.P., Janody D., Ricard Y., Diebold M.D., Gari M., et al. Cutaneous mucormycosis in a diabetic woman. Diagnostic and therapeutic problems. Rev Med Intern 1984, 5:298-302.
28. Chakrabarti A., Ghosh A., Prasad G.S., David J.K., Gupta S., Das A., et al. Apophysomyces elegans: an emerging zygomycete in India. J Clin Microbiol 2003, 41:783-788.
29. Stevanovic M.V., Mirzayan R., Holtom P.D., Schnall S.B. Mucormycosis osteomyelitis in the hand. Orthopedics 1999, 22:449-450.
30. Telles Filho F.D.Q., Coelho A., Porto E., Lameira R.F., Freitas M.M., Barboza J., et al. Subcutaneous mucormycosis caused by Rhizopus oryzae probable nosocomial acquired infection. Rev Inst Med Trop Sao Paulo 1985, 27:201-206.
31. Branton M.H., Johnson S.C., Brooke J.D., Hasbargen J.A. Peritonitis due to Rhizopus in a patient undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1991, 13:19-21.
32. Mohadjer Y., Smith M.E., Akduman L. Mucormycosis endophthalmitis after cataract surgery. Ocul Immunol Inflamm 2007, 15:117-120.
33. Locher D.H., Adesina A., Wolf T.C., Imes C.B., Chodosh J. Postoperative Rhizopus scleritis in a diabetic man. J Cataract Refract Surg 1998, 24:562-565.
34. Alba-Loureiro T.C., Munhoz C.D., Martins J.O., Cerchiaro G.A., Scavone C., Curi R., et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007, 40:1037-1044.
35. Peleg A.Y., Weerarathna T., McCarthy J.S., Davis T.M.E. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007, 23:3-13.
36. Foss N.T., Foss-Freitas M.C., Ferreira M.A.N., Cardili R.N., Barbosa C.M.C., Foss M.C. Impaired cytokine production by peripheral blood mononuclear cells in type-1 diabetic patients. Diabetes Metab 2007, 33:439-443.
37. Waldorf A.R., Ruderman N., Diamond R.D. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defence against Rhizopus. J Clin Invest 1984, 74:150-160.
38. Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
39. Ibrahim A.S., Spellberg B., Avanessian V., Fu Y., Edwards J.E. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005, 73:778-783.
40. Waldorf A.R. Pulmonary defence mechanisms against opportunistic fungal pathogens. Immunol Ser 1989, 47:243-271.
41. Jorens P.G., Boelaert J.R., Halloy V., Zamora R., Schneider Y.J., Herman A.G. Human and rat macrophages mediate fungistatic activity against Rhizopus species differently: in vitro and ex vivo studies. Infect Immun 1995, 63:4489-4494.
42. Waldorf A.R., Peter L., Polak A. Mucormycotic infection in mice following prolonged incubation of spores in vivo and the role of spore agglutinating antibodies on spore germination. Sabouraudia 1984, 22:101-108.
43. Marx R.S., Forsyth K.R., Hentz S.K. Mucorales species activation of a serum leukotactic factor. Infect Immun 1982, 38:1217-1222.
44. Waldorf A.R., Halde C., Vedros N.A. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia 1982, 20:217-224.
45. Sheldon W.H., Bauer H. The development of the acute inflammatory response to experimental cutaneous mucormycosis in normal and diabetic rabbits. J Exp Med 1959, 110:845-852.
46. Chinn R.Y., Diamond R.D. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982, 38:1123-1129.
47. Diamond R.D., Haudenschild C.C., Erickson N.F. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982, 38:292-297.
48. Waldorf A.R., Diamond R.D. Cerebral mucormycosis in diabetic mice after intrasinus challenge. Infect Immun 1984, 44:194-195.
49. Gil-Lamaignere C., Simitsopoulou M., Roilides E., Maloukou A., Winn R.M., Walsh T.J. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005, 191:1180-1187.
50. Diamond R.D., Krzesicki R., Epstein B., Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978, 91:313-328.
51. Chamilos G., Lewis R.E., Lamaris G., Walsh T.J., Kontoyiannis D.P. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008, 52:722-724.
52. Chamilos G., Lewis R.E., Hu J., Xiao L., Zal T., Gilliet M., et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008, 105:9367-9372.
53. Beigelman P.M., Warner N.E. Thirty-two fatal cases of severe diabetic ketoacidosis, including a case of mucormycosis. Diabetes 1973, 22:847-850.
54. Abe F., Shibuya H., Tateyama M., Ommura Y., Azumi N., Kimura K. Mucormycosis in diabetic ketoacidosis. Role of unbound iron binding capacity of transferrin. Acta Pathol Jpn 1986, 36:1507-1512.
55. Artis W.M., Fountain J.A., Delcher H.K., Jones H.E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982, 31:1109-1114.
56. Ibrahim A.S., Spellberg B., Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008, 21:620-625.
57. Ibrahim A.S., Gebremariam T., Lin L., Luo G., Husseiny M.I., Skory C.D., et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010, 77:587-604.
58. Liu M., Spellberg B., Phan Q.T., Fu Y., Fu Y., Lee A.S., et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010, 120:1914-1924.
59. Perkhofer S., Kainzner B., Kehrel B.E., Dierich M.P., Nussbaumer W., Lass-Flörl C. Potential antifungal effects of human platelets against zygomycetes in vitro. J Infect Dis 2009, 200:1176-1179.
60. Vignini A., Moroni C., Nanetti L., Raffaelli F., Cester A., Gabrielli O., et al. Alterations of platelet biochemical and functional properties in newly diagnosed type 1 diabetes: a role in cardiovascular risk?. Diabetes Metab Res Rev 2011, 27:277-285.
61. Reed C., Bryant R., Ibrahim A.S., Edwards J., Filler S.G., Goldberg R., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
62. Sun H.-Y., Forrest G., Gupta K.L., Aguado J.M., Lortholary O., Julia M.B., et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010, 90:85-92.
63. Turunc T., Demiroglu Y.Z., Aliskan H., Colakoglu S., Arslan H. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients. Diabetes Res Clin Pract. 2008, 82:203-208.
64. Mantadakis E., Samonis G. Clinical presentation of zygomycosis. Clin Microbiol Infect 2009, 15:15-20.
65. Meas T., Mouly S., Kania R., Hervé D., Herman P., Kévorkian J.P., et al. Zygomycosis: an uncommon cause for peripheral facial palsy in diabetes. Diabetes Metab 2007, 33:227-229.
66. Singh N.P., Garg S., Kumar S., Gulati S. Multiple cranial nerve palsies associated with type-2 diabetes mellitus. Singapore Med J 2006, 47:712-715.
67. Auluck A. Maxillary necrosis by mucormycosis. a case report and literature review. Med Oral Patol Oral Cir Bucal 2007, 12:E360-E364.
68. Chander J., Kaur J., Gulati N., Arora V., Nagarkar N., Sood S., et al. Sudden vision loss caused by rhino-orbital zygomycosis in diabetic patients: case series. Mycoses 2009, 54:e228-e232.
69. Chua J.L.L., Cullen J.F. Fungal pan-sinusitis with severe visual loss in uncontrolled diabetes. Ann Acad Med Singapore 2008, 37:964-967.
70. McAdams H.P., Rosado de Christenson M., Strollo D.C., Patz E.F. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997, 168:1541-1548.
71. Lee F.Y., Mossad S.B., Adal K.A. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999, 159:1301-1309.
72. Economopoulos N., Kelekis D., Papadopoulos A., Kontopoulou C., Brountzos E.N. Subclavian artery occlusion and pseudoaneurysm caused by lung apex mucormycosis: successful treatment with transcatheter embolization. Cardiovasc Intervent Radiol 2007, 30:143-145.
73. Agarwal R., Kumar V., Gupta D. Pulmonary mucormycosis: two of a kind. Eur J Intern Med 2006, 17:63-65.
74. Skiada A., Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect 2009, 15:41-45.
75. Arndt S., Aschendorff A., Echternach M., Daemmrich T.D., Maier W. Rhino-orbital-cerebral mucormycosis and aspergillosis: differential diagnosis and treatment. Eur Arch Otorhinolaryngol 2009, 266:71-76.
76. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F.G.M., Verweij P.E. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45-52.
77. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
78. Nosari A., Anghilieri M., Carrafiello G., Guffanti C., Marbello L., Montillo M., et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 2003, 88:1405-1409.
79. Glazer M., Nusair S., Breuer R., Lafair J., Sherman Y., Berkman N. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 2000, 117:279-282.
80. Alobid I., Bernal M., Calvo C., Vilaseca I., Berenguer J., Alós L. Treatment of rhinocerebral mucormycosis by combination of endoscopic sinus debridement and amphotericin B. Am J Rhinol 2001, 15:327-331.
81. Safder S., Carpenter J.S., Roberts T.D., Bailey N. The Black Turbinate" sign: an early MR imaging finding of nasal mucormycosis. AJNR Am J Neuroradiol 2010, 31:771-774.
82. Hot A., Maunoury C., Poiree S., Lanternier F., Viard J.P., Loulergue P., et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011, 17:409-417.
83. Garcia-Hermoso D., Dannaoui E., Lortholary O., Dromer F. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis. Manual of clinical microbiology 2011, ASM Press.
84. Lass-Flörl C., Resch G., Nachbaur D., Mayr A., Gastl G., Auberger J., et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:e101-e104.
85. Torres-Narbona M., Guinea J., Martínez-Alarcón J., Muñoz P., Peláez T., Bouza E. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol 2008, 46:225-230.
86. Dannaoui E. Molecular tools for identification of zygomycetes and the diagnosis of zygomycosis. Clin Microbiol Infect 2009, 15:66-70.
87. Hofman V., Dhouibi A., Butori C., Padovani B., Gari-Toussaint M., Garcia-Hermoso D., et al. Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient. Diagn Pathol 2010, 5:1.
88. Wang J.L., Hsiao C.H., Chang S.C., Hsueh P.R., Chen Y.C. Diagnostic challenge of zygomycosis in compromised hosts. Med Mycol 2006, 44:19-24.
89. Yohai R.A., Bullock J.D., Aziz A.A., Markert R.J. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994, 39:3-22.
90. Rapidis A.D. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2009, 15:98-102.
91. Odessey E., Cohn A., Beaman K., Schechter L. Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect (Larchmt) 2008, 9:91-98.
92. O'Neill B.M., Alessi A.S., George E.B., Piro J. Disseminated rhinocerebral mucormycosis: a case report and review of the literature. J Oral Maxillofac Surg 2006, 64:326-333.
93. Tedder M., Spratt J.A., Anstadt M.P., Hegde S.S., Tedder S.D., Lowe J.E. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994, 57:1044-1050.
94. Dannaoui E., Meis J.F.G.M., Loebenberg D., Verweij P.E. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003, 47:3647-3650.
95. Ibrahim A.S., Gebremariam T., Fu Y., Edwards J.E., Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556-1558.
96. Spellberg B., Fu Y., Edwards J.E., Ibrahim A.S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830-832.
97. Ibrahim A.S., Edwards J.E., Fu Y., Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070-1073.
98. Ibrahim A.S., Gebermariam T., Fu Y., Lin L., Husseiny M.I., French S.W., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
99. Ibrahim A.S., Gebremariam T., Luo G., Fu Y., French S.W., Edwards J.E., et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation. Polyenes and echinocandins. Antimicrob Agents Chemother 2011, 55:1768-1770.
100. Ibrahim A.S., Avanessian V., Spellberg B., Edwards J.E. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003, 47:3343-3344.
101. Ibrahim A.S., Bowman J.C., Avanessian V., Brown K., Spellberg B., Edwards J.E., et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005, 49:721-727.
102. Ibrahim A.S., Gebremariam T., Husseiny M.I., Stevens D.A., Fu Y., Edwards J.E., et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008, 52:1573-1576.
103. Lanternier F., Lortholary O. Liposomal amphotericin B: what is its role in 2008?. Clin Microbiol Infect 2008, 14:71-83.
104. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274-282.
105. Lewis R.E., Albert N.D., Liao G., Hou J., Prince R.A., Kontoyiannis D.P. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010, 54:1298-1304.
106. Nosari A., Oreste P., Montillo M., Carrafiello G., Draisci M., Muti G., et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000, 85:1068-1071.
107. Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396.
108. Herbrecht R., Letscher-Bru V., Bowden R.A., Kusne S., Anaissie E.J., Graybill J.R., et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001, 20:460-466.
109. Shoham S., Magill S.S., Merz W.G., Gonzalez C., Seibel N., Buchanan W.L., et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010, 48:511-517.
110. Walsh T.J., Kontoyiannis D.P. Editorial commentary: what is the role of combination therapy in management of zygomycosis?. Clin Infect Dis 2008, 47:372-374.
111. Cornely O.A., Vehreschild J.J., Rüping M.J.G.T. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009, 15:77-81.
112. van Burik J-AH, Hare R.S., Solomon H.F., Corrado M.L., Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
113. Lebeaux D., Lanternier F., Elie C., Suarez F., Buzyn A., Viard J.-P., et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009, 53:5224-5229.
114. Spellberg B., Andes D., Perez M., Anglim A., Bonilla H., Mathisen G.E., et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009, 53:3122-3125.
115. Spellberg B., Ibrahim A.S., Chin-Hong P.V., Kontoyiannis D.P., Morris M.I., Perfect J.R., et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2011, 67(3):715-722.
116. Verweij P.E., González G.M., Wiedrhold N.P., Lass-Flörl C., Warn P., Heep M., et al. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother 2009, 21:272-281.
117. Chakrabarti A., Shivaprakash M.R., Curfs-Breuker I., Baghela A., Klaassen C.H., Meis J.F. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol 2010, 48:4580-4585.
118. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503-509.
119. Spellberg B., Walsh T.J., Kontoyiannis D.P., Edwards J., Ibrahim A.S. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009, 48:1743-1751.